Stock Analysis

Khandwala Securities Third Quarter 2025 Earnings: EPS: ₹0.35 (vs ₹0.18 in 3Q 2024)

NSEI:KHANDSE
Source: Shutterstock

Khandwala Securities (NSE:KHANDSE) Third Quarter 2025 Results

Key Financial Results

  • Revenue: ₹30.4m (up 42% from 3Q 2024).
  • Net income: ₹5.39m (up 102% from 3Q 2024).
  • Profit margin: 18% (up from 13% in 3Q 2024). The increase in margin was driven by higher revenue.
  • EPS: ₹0.35 (up from ₹0.18 in 3Q 2024).
earnings-and-revenue-history
NSEI:KHANDSE Earnings and Revenue History February 13th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Khandwala Securities' share price is broadly unchanged from a week ago.

Risk Analysis

It's necessary to consider the ever-present spectre of investment risk. We've identified 3 warning signs with Khandwala Securities (at least 1 which shouldn't be ignored), and understanding them should be part of your investment process.

Valuation is complex, but we're here to simplify it.

Discover if Khandwala Securities might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About NSEI:KHANDSE

Khandwala Securities

Provides stock broking, investment banking, portfolio management, and research analyst and investment advisory services in India.

Adequate balance sheet with acceptable track record.

Community Narratives

AstraZeneca's Oncology and Obesity Innovations Will Drive Revenue Growth by 10%
Fair Value SEK 2.55k|37.11% undervalued
Unike
Unike
Community Contributor
Leading the Charge in SME SaaS Innovation
Fair Value SEK 100.02|23.535% undervalued
Investingwilly
Investingwilly
Community Contributor
Brookfield Corporation is a solid BUY for a long-term portfolio
Fair Value CA$82.23|1.7389999999999999% overvalued
Jonataninho
Jonataninho
Community Contributor